MY197202A - A liquid formulation of anti-tnf alpha antibody - Google Patents

A liquid formulation of anti-tnf alpha antibody

Info

Publication number
MY197202A
MY197202A MYPI2019005331A MYPI2019005331A MY197202A MY 197202 A MY197202 A MY 197202A MY PI2019005331 A MYPI2019005331 A MY PI2019005331A MY PI2019005331 A MYPI2019005331 A MY PI2019005331A MY 197202 A MY197202 A MY 197202A
Authority
MY
Malaysia
Prior art keywords
liquid formulation
tnf alpha
alpha antibody
antibody
tnf
Prior art date
Application number
MYPI2019005331A
Inventor
So Ra Yun
Youn Kyung Ko
Jineon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY197202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MY197202A publication Critical patent/MY197202A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464436Cytokines
    • A61K39/464438Tumor necrosis factors [TNF], CD70
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a liquid formulation of an anti-TNF-? antibody, specifically to a liquid formulation of adalimumab. The most illustrative drawing: FIGURE 2
MYPI2019005331A 2017-03-16 2018-03-16 A liquid formulation of anti-tnf alpha antibody MY197202A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (en) 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibody

Publications (1)

Publication Number Publication Date
MY197202A true MY197202A (en) 2023-05-31

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019005331A MY197202A (en) 2017-03-16 2018-03-16 A liquid formulation of anti-tnf alpha antibody

Country Status (15)

Country Link
JP (2) JP7109849B2 (en)
KR (2) KR20180106974A (en)
CN (1) CN110621303A (en)
AU (1) AU2018236651B2 (en)
BR (1) BR112019019162A2 (en)
CO (1) CO2019010860A2 (en)
MA (1) MA46988A1 (en)
MX (1) MX2019010895A (en)
MY (1) MY197202A (en)
NZ (1) NZ757965A (en)
PH (1) PH12019502075A1 (en)
RU (1) RU2756619C2 (en)
UA (1) UA123847C2 (en)
WO (1) WO2018169348A1 (en)
ZA (1) ZA201906696B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210114989A (en) 2019-02-18 2021-09-24 일라이 릴리 앤드 캄파니 therapeutic antibody formulation
CA3133577A1 (en) * 2019-03-18 2020-09-24 Alvotech Hf Aqueous formulations of tnf-alpha antibodies in high concentrations
US11596690B2 (en) * 2019-03-21 2023-03-07 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-IL-33 antibodies
WO2021164717A1 (en) * 2020-02-20 2021-08-26 百奥泰生物制药股份有限公司 ANTI-TNF-α ANTIBODY PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5919606B2 (en) * 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド Improved high concentration anti-TNF alpha antibody liquid formulation
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
BR112014021325A2 (en) * 2012-03-07 2017-08-22 Cadila Healthcare Ltd LIQUID PHARMACEUTICAL FORMULATION AND LYOPHILIZED FORMULATION
PE20191815A1 (en) * 2012-09-07 2019-12-27 Coherus Biosciences Inc STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB
CA2898262A1 (en) * 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
JP2016515515A (en) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC Anti-prolactin receptor antibody preparation
US20150274819A1 (en) * 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
IN2014MU01248A (en) * 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
DK2946765T3 (en) * 2014-05-23 2016-10-31 Ares Trading Sa Liquid pharmaceutical composition
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (en) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Pharmaceutical anti-tnfalpha antibody formulation
TW201636047A (en) * 2015-01-28 2016-10-16 麥博賽恩斯有限公司 Pharmaceutical formulations for anti-TNF-alpha antibodies
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
RU2019130728A3 (en) 2021-04-16
RU2756619C2 (en) 2021-10-04
BR112019019162A2 (en) 2020-04-14
RU2019130728A (en) 2021-04-16
PH12019502075A1 (en) 2020-09-14
JP2022097600A (en) 2022-06-30
MX2019010895A (en) 2019-11-05
AU2018236651A1 (en) 2019-10-31
CO2019010860A2 (en) 2020-01-17
KR102342292B1 (en) 2021-12-24
JP7109849B2 (en) 2022-08-01
KR20180106974A (en) 2018-10-01
AU2018236651B2 (en) 2020-12-10
NZ757965A (en) 2022-07-01
MA46988A1 (en) 2020-06-30
KR20200096472A (en) 2020-08-12
JP2020510079A (en) 2020-04-02
CN110621303A (en) 2019-12-27
WO2018169348A1 (en) 2018-09-20
UA123847C2 (en) 2021-06-09
ZA201906696B (en) 2020-08-26

Similar Documents

Publication Publication Date Title
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
CL2022000448A1 (en) Autoinjector (divisional application no. 201903061)
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
MX2020009649A (en) Monoclonal antibodies against bcma.
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MY190297A (en) Anti-pd1 antibodies and methods of use
MX2020010951A (en) Anti-hla-g antibodies and use thereof.
MX2017003478A (en) Anti-fgfr2/3 antibodies and methods using same.
MY191581A (en) Anti-pd-1 antibodies
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
EA201791029A1 (en) ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
PH12018550160A1 (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
MX2023006415A (en) Antibodies, uses & methods.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
SG11201811429XA (en) Flow reactor
PH12019502694A1 (en) Anti-trkb antibodies
MX2018009218A (en) Cgrp antibodies and uses thereof.
MY195448A (en) New Anti-Sirpa Antibodies and Their Therapeutic Applications
MX2017016258A (en) Aml antigens and uses thereof.